Novavax, Inc.

NASDAQ:NVAX  
126.25
-2.91 (-2.25%)
4:02:20 PM EDT: $126.34 +0.09 (+0.07%)
Products, Other Pre-Announcement

Novavax Reports Q3 Rev Of $157 Million Versus $2.5 Million

Published: 11/09/2020 22:37 GMT
Novavax Inc (NVAX) - Novavax Reports Third Quarter 2020 Financial and Operational Results.
Q3 Loss per Share $3.21.
Q3 Revenue $157 Million Versus $2.5 Million.
Q3 Earnings per Share Estimate $1.73 -- Refinitiv Ibes Data (analyst estimates).
Q3 Revenue Estimate $230.6 Million -- Refinitiv Ibes Data (analyst estimates).
Secured Additional Large-scale Manufacturing for Nvx-cov2373 With Expected Global Capacity Over Two Billion Doses by Mid-2021.
For Nvx-cov2373 Uk Phase 3 Interim Data Expected As Soon As Early Q1 2021.
Research and Development Expenses Increased to $294.1 Million in Q3 of 2020, Compared to $18.6 Million in Same Period in 2019.
Qtrly Research and Development Expenses Include Expense of $187.2 Million Associated With Manufacturing Supply Agreements for Nvx-cov2373.
Novavax - As of Sept 30, Had $571.6 Million in Cash, Equivalents, Marketable Securities & Restricted Cash, Versus $82.2 Million As of Dec 31, 2019.